Androgens, growth factors, and risk of prostate cancer: The multiethnic cohort

Prostate

Volumn 70, Issue 8, 2010, Pages 906-915

  Gill, Jasmeet K ^a   Wilkens, Lynne R ^b   Pollak, Michael N ^c   Stanczyk, Frank Z ^d   Kolonel, Laurence N ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Androgens; Ethnicity; IGFs; Prostate cancer; Risk

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; ANDROSTANEDIOL GLUCURONIDE; ANDROSTANOLONE; CONNECTIVE TISSUE GROWTH FACTOR; GROWTH FACTOR; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN AMERICAN; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; DIET RESTRICTION; GROUPS BY AGE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; CASE CONTROL STUDY; ETHNOLOGY; METABOLISM; MIDDLE AGED; PATIENT SELECTION; PROSTATE TUMOR; QUESTIONNAIRE; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR;

AGED; ANDROGENS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; PATIENT SELECTION; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 77952318705     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21125     Document Type: Article

References (28)

1. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149(7):461-471, W468-W483.
2. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100(3):170-183.
3. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS. A multiethnic cohort in Hawaii and Los Angeles: Baseline characteristics. Am J Epidemiol 2000;151(4):346-357.
4. Goebelsmann UBGS, Gale JA, Kletzky OA, Nakamura RM, Coulson AH, Korelitz JJ, Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. In: Lepow IH, editors. Vasectomy: Immunologic and pathophysiologic effects in animals and man. New York: Academic Press; 1979. pp 165-175.
5. Serafini P, Ablan F, Lobo RA. 5 Alpha-reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 1985;60(2):349-355. (Pubitemid 15129583)
6. Narang RRJ, Savjani G, Peterson J, Gentzschein E, Stanczyk FZ, Radioimmunoassay kit for the quantitative measurement of androstanediol glucuronide in unextracted serum. The 17th National Meeting of the Clinical Ligand Assay Society. Chicago, IL; 1991.
7. Dorgan JF, Albanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M, McShane LM, Barrett MJ, Tangrea J, Taylor PR. Relationships of serum androgens and estrogens to prostate cancer risk: Results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev 1998;7(12):1069-1074. (Pubitemid 29001661)
8. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(1):86-91.
9. Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001;57(5):930-935. (Pubitemid 32405316)
10. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE. Endogenous sex hormones and prostate cancer risk: A case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003;12(12):1410-1416. (Pubitemid 38031742)
11. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88(16):1118-1126. (Pubitemid 26274606)
12. Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, Egevad L, Gann PH, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjonneland A, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Sieri S, Vineis P, Palli D, Quiros JR, Ardanaz E, Chirlaque MD, Larranaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Bikou C, Trichopoulos D, Stattin P, Jenab M, Ferrari P, Slimani N, Riboli E, Kaaks R. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007;121(6):1331-1338. (Pubitemid 47293802)
13. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, Crawford ED, Andriole GL, Kaaks R, Hayes RB. Endogenous sex hormones and the risk of prostate cancer:Aprospective study. Int J Cancer 2008;122(10):2345-2350. (Pubitemid 351542341)
14. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50(1):169-173. (Pubitemid 20030013)
15. Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, Reunanen A, Knekt P. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: A longitudinal study. Cancer 1999;86(2):312-315. (Pubitemid 29327588)
16. Hsing AW, Comstock GW. Serological precursors of cancer: Serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993;2(1):27-32.
17. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman UH, Hakama M. High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study. Int J Cancer 2004;108(3):418-424.
18. Tsai CJ, Cohn BA, Cirillo PM, Feldman D, Stanczyk FZ, Whittemore AS. Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: A longitudinal study in African-Americans and Caucasians (United States). Cancer Causes Control 2006;17(10):1237-1244. (Pubitemid 44772823)
19. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjonneland A, Gronbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quiros JR, Ardanaz E, Navarro C, Larranaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: Results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007;16(6): 1121-1127.
20. Lacey JV Jr, Hsing AW, Fillmore CM, Hoffman S, Helzlsouer KJ, Comstock GW. Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomarkers Prev 2001;10(10):1101-1102.
21. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16(3):255-262. (Pubitemid 40897844)
22. Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15(6):1137-1141.
23. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Chia D, Crawford ED, Kaaks R, Hayes RB. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 2007;121(10):2267-2273. (Pubitemid 47585608)
24. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63(14):3991-3994. (Pubitemid 36917917)
25. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94(14):1099-1106. (Pubitemid 34830730)
26. Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 2007;28(10):2154-2159.
27. Li L, Yu H, Schumacher F, Casey G, Witte JS. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003;14(8):721-726.
28. Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002; 52(2):98-105.